NBPF5P

Across TCGA pan-cancer cohorts, NBPF5P RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated NBPF5P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NBPF5P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NBPF5P expression acts as an unfavorable survival marker, although some lineages such as PAAD and OV show a favorable association.

LIHC, COAD, and CHOL are the cancer types where NBPF5P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.240	0.554	<.001	72	view →
COAD	DFS	Tertile	II,III,IV	0.577	0.771	.002	57	view →
CHOL	DFS	Tertile	All	0.045	0.497	.029	36	view →
LGG	OS	Tertile	All	0.349	0.814	<.001	36	view →
UCEC	DFS	Tertile	All	0.261	0.671	<.001	30	view →
PAAD	OS	Tertile	II,III,IV	1.000	0.363	.032	27	view →
OV	DFS	Tertile	IV	1.000	0.229	.006	24	view →
KIRP	DFS	Tertile	All	0.218	0.771	.029	18	view →
ACC	DFS	Tertile	II,III,IV	0.242	0.724	.034	18	view →
BRCA	OS	Quartile	III,IV	0.983	0.883	.017	12	view →
SKCM	DFS	Tertile	III,IV	0.433	0.700	.012	12	view →
HNSC	DFS	Tertile	IV	0.309	0.679	.001	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

NBPF5P–LIHC (DFS)

Open the LIHC breakdown →